TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.52
−1.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 53.8M | 62.4M | 42.1M | 36.5M | 24.9M |
| Cost of Revenue | 942.0K | 2.3M | — | — | — |
| Gross Profit | 52.9M | 60.1M | 42.1M | 36.5M | 24.9M |
| Operating Expenses | |||||
| R&D Expense | 134.4M | 132.2M | 143.9M | 115.2M | 105.9M |
| SG&A Expense | 56.5M | 41.5M | 43.7M | 35.5M | 30.0M |
| General & Admin Expense | 56.5M | 41.5M | 43.7M | 35.5M | 30.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.7M) | (2.3M) | — | — | — |
| Total Operating Expenses | 189.2M | 171.4M | 187.7M | 150.7M | 135.9M |
| Cost and Expenses | 190.2M | 173.7M | 187.7M | 150.7M | 135.9M |
| Operating Income (EBIT) | (136.3M) | (111.3M) | (145.6M) | (114.2M) | (111.1M) |
| Non-Operating | |||||
| Interest Income | 8.7M | 5.6M | 7.9M | 6.6M | 1.5M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 8.7M | 5.6M | 7.9M | 6.6M | 1.5M |
| Other Non-Op Income/Expense | 12.6M | 9.7M | 15.5M | 12.6M | 2.9M |
| Non-Operating Income (excl Interest) | (12.6M) | (9.7M) | (15.5M) | (12.6M) | (2.9M) |
| EBT (Pre-Tax Income) | (123.8M) | (101.6M) | (130.1M) | (101.6M) | (108.1M) |
| Income Tax Expense | (63.0K) | 4.0K | 208.0K | 134.0K | 54.0K |
| Bottom Line | |||||
| Net Income | (123.7M) | (101.6M) | (130.3M) | (101.7M) | (108.2M) |
| Earnings from Cont. Ops | (123.7M) | (101.6M) | (130.3M) | (101.7M) | (108.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (123.7M) | (101.6M) | (130.3M) | (101.7M) | (108.2M) |
| Per Share | |||||
| Basic EPS | ($0.85) | ($0.87) | ($1.19) | ($1.08) | ($1.23) |
| Diluted EPS | ($0.85) | ($0.87) | ($1.19) | ($1.08) | ($1.23) |
| Revenue Per Share | $0.36 | $0.54 | $0.39 | $0.39 | $0.28 |
| Shares | |||||
| Basic Shares Outstanding | 149.9M | 116.2M | 109.2M | 94.6M | 87.8M |
| Diluted Shares Outstanding | 149.9M | 116.2M | 109.2M | 94.6M | 87.8M |
| Profitability Metrics | |||||
| EBITDA | (122.3M) | (99.3M) | (127.6M) | (99.2M) | (106.5M) |
| D&A | 1.5M | 2.3M | 2.5M | 2.4M | 1.6M |
| EBIT | (123.8M) | (101.6M) | (130.1M) | (101.6M) | (108.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026